HC Wainwright Issues Positive Forecast for Personalis (NASDAQ:PSNL) Stock Price

Personalis (NASDAQ:PSNL - Free Report) had its target price lifted by HC Wainwright from $8.00 to $9.00 in a research report report published on Wednesday, Marketbeat Ratings reports. The firm currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on PSNL. Needham & Company LLC restated a "buy" rating and issued a $7.00 target price on shares of Personalis in a report on Thursday, April 10th. Craig Hallum began coverage on Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 target price for the company. Finally, Lake Street Capital upped their price target on Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Personalis presently has a consensus rating of "Buy" and an average target price of $8.00.

Personalis Stock Performance

NASDAQ PSNL traded down $0.12 on Wednesday, hitting $5.04. 784,838 shares of the stock were exchanged, compared to its average volume of 1,000,025. Personalis has a 52-week low of $1.14 and a 52-week high of $7.20. The stock has a fifty day moving average price of $3.67 and a two-hundred day moving average price of $4.46. The firm has a market capitalization of $445.07 million, a P/E ratio of -3.00 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Sell-side analysts expect that Personalis will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Personalis

Hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock worth $62,000 after acquiring an additional 2,724 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Personalis during the 4th quarter valued at about $28,000. Stifel Financial Corp grew its position in Personalis by 25.0% in the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock worth $144,000 after acquiring an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Personalis by 2,827.0% during the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after buying an additional 5,654 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in Personalis by 25.6% during the fourth quarter. Two Sigma Advisers LP now owns 34,300 shares of the company's stock worth $198,000 after purchasing an additional 7,000 shares during the period. Institutional investors and hedge funds own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.